These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24171147)

  • 1. Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study.
    McElroy SL; Guerdjikova AI; Kim DD; Burns C; Harris-Collazo R; Landbloom R; Dunayevich E
    Prim Care Companion CNS Disord; 2013; 15(3):. PubMed ID: 24171147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).
    Iosifescu DV; Jones A; O'Gorman C; Streicher C; Feliz S; Fava M; Tabuteau H
    J Clin Psychiatry; 2022 May; 83(4):. PubMed ID: 35649167
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
    J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
    Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
    J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
    Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
    J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study.
    Dichtel LE; Nyer M; Dording C; Fisher LB; Cusin C; Shapero BG; Pedrelli P; Kimball AS; Rao EM; Mischoulon D; Fava M; Miller KK
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder.
    Rele S; Millet R; Kim S; Paik JW; Kim S; Masand PS; Patkar AA
    Prim Care Companion CNS Disord; 2015; 17(4):. PubMed ID: 26693034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study.
    Song HR; Bahk WM; Woo YS; Jeong JH; Kwon YJ; Seo JS; Kim W; Kim MD; Shin YC; Lee SY; Min KJ
    Clin Psychopharmacol Neurosci; 2015 Aug; 13(2):144-9. PubMed ID: 26243840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
    Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C
    Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.